Compare Enveric Biosciences Inc (ENVB) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sirius XM Holdings Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Sirius XM Holdings Inc trades at $31.24 (market cap $10.32B). The key difference: Sirius XM Holdings Inc is far larger — about 1939.8× Enveric Biosciences Inc's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SIRI | |
|---|---|---|
Market Cap | $5.32M | $10.32B |
Sector | Health | Media |
52-Week High | $17.40 | $30.75 |
52-Week Low | $1.28 | $19.92 |
Enterprise Value | $408.82K | $19.99B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Sirius XM Holdings (SIRI) trades at $31.16, up 2.53% today, with a bullish technical outlook supported by moving averages. The stock shows solid fundamentals with a P/E of 12.99, P/B of 0.88, and net income margin of 9.86%. Recent Q1 2026 earnings beat expectations, and the company announced a $0.27 dividend for H1 2026. Positive sentiment is driven by a new YouTube ad partnership and inclusion in the S&P MidCap 400 index as of June 2026.
The outlook is positive with analyst consensus favoring Buy (58% of ratings) and a $31.17 price target. Key opportunities include revenue growth from digital advertising and strong cash flow. Risks involve competitive pressures in media and high debt levels. The stock remains attractive for value and income investors, though monitoring Q2 2026 earnings on July 30, 2026, is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
